Thymectomy promotes maintained complete stable remission in myasthenia gravis

Area of Science:

• Neurology
• Immunology
• Surgical Oncology

Background:

• Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease.
• Long-term prognosis and remission rates in MG patients remain a significant clinical challenge.
• Evaluating surgical interventions like thymectomy is crucial for improving MG management.

Purpose of the Study:

• To assess the impact of thymectomy on the long-term prognosis of myasthenia gravis patients.
• To determine the efficacy of thymectomy in achieving maintainable complete stable remission (mCSR).
• To identify patient subgroups that benefit most from thymectomy for MG.

Main Methods:

• Retrospective analysis of prospectively collected data from a large MG patient database.
• Definition of mCSR as symptom-free status and cessation of all MG treatments for at least one year.
• Application of Kaplan-Meier curves and multivariable Cox proportional hazards models to analyze outcomes.

Main Results:

• Thymectomy patients demonstrated significantly higher mCSR rates (12.2%) compared to conservative treatment (4.3%).
• Thymectomy was an independent predictor of mCSR in the overall cohort (HR=3.40) and non-thymomatous MG subgroup (HR=5.56).
• Significant benefits of thymectomy for mCSR were noted in early-onset MG, females, and ocular MG patients.

Conclusions:

• Thymectomy is a beneficial treatment for myasthenia gravis patients seeking long-term remission.
• The positive impact of thymectomy extends to specific subgroups, including ocular and non-thymomatous MG.
• Surgical intervention through thymectomy offers a promising pathway to improved prognosis in MG.